Synthesis and application of the MCM-41 and SBA-15 as matrices for in vitro efavirenz release study
-
Published:2016-02
Issue:
Volume:31
Page:153-159
-
ISSN:1773-2247
-
Container-title:Journal of Drug Delivery Science and Technology
-
language:en
-
Short-container-title:Journal of Drug Delivery Science and Technology
Author:
Jesus R.A.,
Rabelo A.S.,
Figueiredo R.T.,
Cides da Silva L.C.,
Codentino I.C.,
Fantini M.C.A.,
Araújo G.L.B.,
Araújo A.A.S.,
Mesquita M.E.ORCID
Subject
Pharmaceutical Science
Reference28 articles.
1. Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients;Brettle;Int. J. STD AIDS,1998
2. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase;Ren;Structure,2000
3. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase;Young;Antimicrob. Agents Chemother.,1995
4. Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection;Matthews;J. Pharm. Biomed. Anal.,2002
5. Biochemical effects of chronic administration of efavirenz on the intracranial auditory relay centers of adult Wistar rats;Adjene;Genom. Med. Biomark. Health Sci.,2012
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献